NO20020829L - Ny anvendelse av docetaxel for behandling av hepatoma - Google Patents

Ny anvendelse av docetaxel for behandling av hepatoma

Info

Publication number
NO20020829L
NO20020829L NO20020829A NO20020829A NO20020829L NO 20020829 L NO20020829 L NO 20020829L NO 20020829 A NO20020829 A NO 20020829A NO 20020829 A NO20020829 A NO 20020829A NO 20020829 L NO20020829 L NO 20020829L
Authority
NO
Norway
Prior art keywords
docetaxel
treatment
hepatoma
new use
hepatocellular carcinoma
Prior art date
Application number
NO20020829A
Other languages
English (en)
Other versions
NO20020829D0 (no
NO328527B1 (no
Inventor
Chin-Wen Chi
Heng-Liang Lin
Tsung-Yun Liu
Wing-Yiu Liu
Gar-Yang Chau
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20020829L publication Critical patent/NO20020829L/no
Publication of NO20020829D0 publication Critical patent/NO20020829D0/no
Publication of NO328527B1 publication Critical patent/NO328527B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NO20020829A 1999-08-31 2002-02-20 Ny anvendelse av docetaxel for behandling av hepatoma NO328527B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9920548.6A GB9920548D0 (en) 1999-08-31 1999-08-31 Treatment of hepatocellular carcinoma
PCT/EP2000/008782 WO2001015675A2 (en) 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma

Publications (3)

Publication Number Publication Date
NO20020829L true NO20020829L (no) 2002-02-20
NO20020829D0 NO20020829D0 (no) 2002-02-20
NO328527B1 NO328527B1 (no) 2010-03-08

Family

ID=10860081

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020829A NO328527B1 (no) 1999-08-31 2002-02-20 Ny anvendelse av docetaxel for behandling av hepatoma

Country Status (34)

Country Link
US (2) US20030158249A1 (no)
EP (1) EP1214061B1 (no)
JP (1) JP4866522B2 (no)
KR (1) KR100670416B1 (no)
CN (1) CN1174748C (no)
AT (1) ATE269700T1 (no)
AU (1) AU777583B2 (no)
BG (1) BG65913B1 (no)
BR (1) BR0013625A (no)
CA (1) CA2382294C (no)
CZ (1) CZ301378B6 (no)
DE (1) DE60011794T2 (no)
DK (1) DK1214061T3 (no)
EA (1) EA004804B1 (no)
EE (1) EE05124B1 (no)
ES (1) ES2218223T3 (no)
GB (1) GB9920548D0 (no)
HK (1) HK1048944B (no)
HR (1) HRP20020171A2 (no)
HU (1) HU228861B1 (no)
IL (2) IL147489A0 (no)
ME (1) MEP7809A (no)
MX (1) MXPA02002041A (no)
NO (1) NO328527B1 (no)
NZ (1) NZ517604A (no)
PL (1) PL212612B1 (no)
PT (1) PT1214061E (no)
RS (1) RS50148B (no)
SI (1) SI1214061T1 (no)
SK (1) SK286378B6 (no)
TW (1) TW589180B (no)
UA (1) UA72927C2 (no)
WO (1) WO2001015675A2 (no)
ZA (1) ZA200201408B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268619C (zh) 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 多烯紫杉醇三水化合物的制备方法
ATE427943T1 (de) * 2003-12-12 2009-04-15 Quiral Quimica Do Brasil Verfahren zur herstellung von wasserfreien und hydratisierten pharmazeutischen wirkstoffen (apis); aus diesen hergestellte stabile pharmazeutische zusammensetzungen und anwendungen fur diese zusammensetzungen
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
NZ592132A (en) * 2005-08-31 2012-12-21 Abraxis Bioscience Llc Composition comprising nanoparticles of docitaxel and a citrate
EP2404594B1 (en) * 2005-08-31 2017-12-20 Abraxis BioScience, LLC Compositions comprising docetaxel with increased stability
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
EP2146695A4 (en) * 2007-04-23 2010-05-19 Sun Pharmaceuticals Ind Ltd PHARMACEUTICAL COMPOSITIONS
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
ES2675212T3 (es) 2010-03-26 2018-07-09 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
WO2011139899A2 (en) * 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
WO2016134066A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629819B1 (fr) * 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
CA2150372C (en) * 1993-01-19 2002-08-20 Nancy L. Mills Stable oral ci-981 formulation and process of preparing same
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
DE69737510T2 (de) * 1996-12-30 2007-12-06 Battelle Memorial Institute, Columbus Verwendung eines unverkapselten Antikrebs-Arzneimittels zur Herstellung einer Zubereitung zur Behandlung von Neoplasmen durch Inhalation
CA2294981C (en) * 1997-06-27 2012-04-03 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
ATE233104T1 (de) * 1997-09-18 2003-03-15 Janssen Pharmaceutica Nv Kondensierte imidazolderivate zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
AU1289899A (en) * 1997-10-31 1999-05-24 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
JP2002533387A (ja) * 1998-12-23 2002-10-08 ジー．ディー．サール ＆ カンパニー 腫瘍治療の複合療法としてインテグリン拮抗物質と一つ以上の抗腫瘍剤を使用する方法
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
BRPI0610344A2 (pt) * 2005-12-13 2016-11-29 Teva Pharma forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal

Also Published As

Publication number Publication date
ME00624B (me) 2011-12-20
IL147489A0 (en) 2002-08-14
NZ517604A (en) 2004-04-30
ES2218223T3 (es) 2004-11-16
AU777583B2 (en) 2004-10-21
HRP20020171A2 (en) 2004-02-29
JP4866522B2 (ja) 2012-02-01
CN1372466A (zh) 2002-10-02
HU228861B1 (hu) 2013-06-28
US20030158249A1 (en) 2003-08-21
CA2382294C (en) 2008-06-03
HUP0203197A3 (en) 2005-01-28
BG106460A (bg) 2002-09-30
ZA200201408B (en) 2003-07-30
SI1214061T1 (en) 2004-12-31
DE60011794D1 (de) 2004-07-29
ATE269700T1 (de) 2004-07-15
AU7516800A (en) 2001-03-26
EE200200087A (et) 2003-04-15
KR100670416B1 (ko) 2007-01-17
EP1214061A2 (en) 2002-06-19
MEP7809A (en) 2011-12-20
JP2003508427A (ja) 2003-03-04
PL212612B1 (pl) 2012-10-31
DK1214061T3 (da) 2004-11-01
TW589180B (en) 2004-06-01
EA200200313A1 (ru) 2002-08-29
EE05124B1 (et) 2009-02-16
EP1214061B1 (en) 2004-06-23
WO2001015675A3 (en) 2001-09-20
HK1048944B (zh) 2005-04-22
RS50148B (sr) 2009-05-06
NO20020829D0 (no) 2002-02-20
WO2001015675A2 (en) 2001-03-08
MXPA02002041A (es) 2002-08-20
PT1214061E (pt) 2004-09-30
HK1048944A1 (en) 2003-04-25
CN1174748C (zh) 2004-11-10
US20080045584A1 (en) 2008-02-21
CZ301378B6 (cs) 2010-02-03
BR0013625A (pt) 2002-05-14
CA2382294A1 (en) 2001-03-08
BG65913B1 (bg) 2010-05-31
NO328527B1 (no) 2010-03-08
GB9920548D0 (en) 1999-11-03
SK286378B6 (sk) 2008-08-05
UA72927C2 (uk) 2005-05-16
YU11402A (sh) 2005-07-19
SK2712002A3 (en) 2002-07-02
IL147489A (en) 2006-06-11
DE60011794T2 (de) 2005-07-14
PL353198A1 (en) 2003-11-03
KR20020060166A (ko) 2002-07-16
CZ2002739A3 (cs) 2002-06-12
EA004804B1 (ru) 2004-08-26
HUP0203197A2 (hu) 2003-01-28

Similar Documents

Publication Publication Date Title
NO20020829D0 (no) Ny anvendelse av docetaxel for behandling av hepatoma
ATE486840T1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
HUP0104709A2 (hu) Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására
DE60204966D1 (de) Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
DE60128100D1 (de) Analgetisches arzneimittel
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
DE60229414D1 (de) Verwendung von aplidine in der behandlung von pankreaskrebs
NO20032597D0 (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
DE60023321D1 (de) Zusammensetzung gegen Coccidiose
ATE350038T1 (de) Pharmazeutische zubereitungen enthaltend nanopartikel von 2-(4-ethoxy-phenyl)-3-(4- methansulphonyl-phenyl)-pyrazolo 1,5-böpyridazi
ATE362480T1 (de) Phenanthridinderivate und phenanthridin enthaltende antitumorale arzneimittel
TW200744581A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees